SBSofia Bogiatzi

Sofia Bogiatzi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sofia Bogiatzi has a total of 30 co-authors. Here are the top co-authors by number of shared publications:

  • Ahmad Yatim

    Department of Dermatology, Lausanne University Hospital CHUV and University of Lausanne, Lausanne, Switzerland

    1 shared publication
  • Amélie Osio

    Pathology Department Saint‐Louis Hospital Paris France

    1 shared publication
  • Angela Estenaga

    Pathology Department Saint‐Louis Hospital Paris France

    1 shared publication
  • Antoine Girardin

    Department of Dermatology, Lausanne University Hospital CHUV and University of Lausanne, Lausanne, Switzerland

    1 shared publication
  • Baptiste Louveau

    Solid Tumor Genomics Department Saint‐Louis Hospital Paris France

    1 shared publication
  • Bernard Cribier

    Dermatopathology Unit, Clinique Dermatologique Hôpitaux Universitaires de Strasbourg Strasbourg France

    1 shared publication

Latest Publications

  • Top Cited Papers
    Open Access

    Immune modules to guide diagnosis and personalized treatment of inflammatory skin diseases

    by Teofila Seremet, Jeremy Di Domizio, Antoine Girardin, Ahmad Yatim, Raphael Jenelten, Francesco Messina, Fanny Saidoune, Christoph Schlapbach, Sofia Bogiatzi, Frederic Minisini, et al.

    Previous advances have identified immune pathways associated with inflammatory skin diseases, leading to the development of targeted therapies. However, there is a lack of molecular approaches that delineate these pathways at the individual patient level for personalized diagnostic and therapeutic guidance. Here, we conduct a cross-comparison of expression profiles from multiple inflammatory skin diseases to identify gene modules defining relevant immune pathways. Seven modules are identified, representing key immune pathways: Th17, Th2, Th1, Type I IFNs, neutrophilic, macrophagic, and eosinophilic. These modules allow the development of a molecular map with high diagnostic efficacy for inflammatory skin diseases and clinico-pathologically undetermined cases. Aligning dominant modules with treatment targets offers a rational framework for treatment selection, improving response rates in both treatment-naïve patients and non-responders to targeted therapies. Overall, our approach offers precision medicine for inflammatory skin diseases, utilizing transcriptional modules to support diagnosis and guide personalized treatment selection.


  • Open Access

    Microsecretory adenocarcinoma of the skin, a novel type of sweat gland carcinoma: Report of three additional cases

    by Sofia Bogiatzi, Angela Estenaga, Baptiste Louveau, Amélie Osio, Lydia Deschamps, Samia Mourah, Brigitte Poirot, Jacqueline Lehmann‐Che, Bernard Cribier, Maxime Battistella

    Microsecretory adenocarcinoma (MSA) is a newly described salivary gland tumor harboring a characteristic balanced chromosomal translocation resulting in MEF2C::SS18 gene fusion. Six primary cutaneous MSA cases have been recently described. We report three additional cases confirming the relevance of this recently identified entity of primary cutaneous adnexal tumor. Three patients aged 53‐, 64‐ and 78‐year‐old were retrospectively diagnosed with MSA of the skin (MSAS) as consultation cases of the CARADERM (CAncers RAres DERMatologiques) national network. The clinical presentation was an indolent nodule on the upper extremities. There was no history of salivary gland tumor. Histopathologically, the tumors presented as dermal nodular proliferation with slightly infiltrative borders, composed of cribriform and microcystic structures with abundant myxoid intraluminal secretion embedded in a fibromyxoid stroma. They diffusely expressed cytokeratin 8 and SOX10, focally p63 and heterogeneously smooth muscle actin. All tumors harbored the MEF2C::SS18 gene fusion. A complete surgical excision was performed. No local recurrence or distant metastases were observed so far (follow‐up: 17, 38, and 45 months). MSAS is the cutaneous homologue of MSA of the salivary gland, a low‐grade adnexal neoplasm whose prognosis seems to be excellent once the complete removal of the tumor is assured.